Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosaprepitant dimeglumine + palonosetron hydrochloride + dexamethasone acetate
- Development stage
- Unknown
- Lead developer
- Zhuhai Beihai Biotech
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Fosaprepitant dimeglumine + palonosetron hydrochloride + dexamethasone acetate is a triple-drug antiemetic combination regimen used for the prevention of chemotherapy-induced nausea and vomiting (CINV). The regimen consists of **fosaprepitant dimeglumine**, a prodrug of aprepitant that acts as a neurokinin-1 (NK-1) receptor antagonist; **palonosetron hydrochloride**, a second-generation serotonin (5-HT3) receptor antagonist; and **dexamethasone acetate**, a corticosteroid. This combination targets multiple emetic pathways, addressing both the acute and delayed phases of nausea and vomiting associated with highly or moderately emetogenic chemotherapy. It is currently being evaluated in Phase 2 clinical trials, specifically for patients with esophageal and lung cancer undergoing multi-cycle immunotherapy and chemotherapy, following guidelines from organizations like ASCO that recommend triple-agent prophylaxis for high-risk regimens.
- Other names
- fosaprepitant + palonosetron + dexamethasonefosaprepitant dimeglumine/palonosetron hydrochloride/dexamethasone acetate
02
Targets
GR (Glucocorticoid receptor)TACR1 (Neurokinin‑1 Receptor)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on fosaprepitant dimeglumine + palonosetron hydrochloride + dexamethasone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosaprepitant dimeglumine + palonosetron hydrochloride + dexamethasone acetate.